Bimekizumab 3-year data show durable work-productivity gains in PsA, axSpA
The July 1 abstract reports Year 3 quality-of-life and work-impairment data, not a new pivotal endpoint, from patients who stayed on bimekizumab through open-label extensions of two approved Phase 3 programs.
Executive Summary
- UCB Pharma published a July 1, 2026 abstract showing bimekizumab sustained improvements in health status and work productivity through Year 3 in psoriatic arthritis and axial spondyloarthritis, drawing on open-label extensions of trials that already secured FDA approval Press ReleasePress ReleaseJul 1, 2026.
- The data reported are patient-reported EQ VAS scores and work-impairment measures, not the ACR50 response that BE COMPLETE (NCT03896581) registered as its primary endpoint, so this abstract extends the durability story rather than re-testing pivotal efficacy NCT03896581+1A Study to Evaluate the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic ArthritisNCT03896581Press ReleaseJul 1, 2026.
- Because bimekizumab was already approved for psoriatic arthritis in September 2024 and already beat risankizumab head-to-head on ACR50 in the May 2026 BE BOLD readout, this abstract reinforces an established competitive position rather than resolving new uncertainty.
- No placebo or active comparator arm accompanies the Year 3 figures, and the abstract supplies no confidence intervals, limiting how much the reported improvements can be attributed to the drug versus the open-label, uncontrolled follow-up design Press ReleasePress ReleaseJul 1, 2026.
The data
The abstract reports that among 1,112 psoriatic arthritis patients and 586 axial spondyloarthritis patients followed into open-label extensions, mean EQ visual analog scale scores improved 17.1 to 17.3 points for psoriatic arthritis and 20.2 to 21.3 points for axial spondyloarthritis from baseline to Year 3 Press ReleasePress ReleaseJul 1, 2026. Most patients also reported clinically meaningful improvement in work impairment: 71.2% to 71.3% for psoriatic arthritis and 74.2% to 81.1% for axial spondyloarthritis Press ReleasePress ReleaseJul 1, 2026. In the United States, annualized productivity cost savings reached $13,327.60 to $16,428.25 for psoriatic arthritis patients and $22,012.14 to $22,549.32 for axial spondyloarthritis patients Press ReleasePress ReleaseJul 1, 2026. The report states that 'bimekizumab demonstrated sustained improvements in health status and work productivity to Year 3 across axSpA and PsA,' with health status comparable to population norms Press ReleasePress ReleaseJul 1, 2026.
What the endpoint actually measures
BE COMPLETE (NCT03896581), the pivotal Phase 3 trial underlying this psoriatic arthritis data, registered its primary endpoint as ACR50 response at Week 16, a joint-count-and-function composite measure, not the EQ VAS or work-productivity metrics this abstract reports NCT03896581A Study to Evaluate the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic ArthritisNCT03896581. Those quality-of-life measures were tracked as part of the BE VITAL open-label extension that enrolled patients who completed BE COMPLETE, a single-arm follow-on with no placebo comparison Press ReleasePress ReleaseJul 1, 2026. ClinicalTrials.gov posted results for BE COMPLETE confirm the ACR50 endpoint was analyzed under a randomized, placebo-controlled design at Week 16, a data quality tier the Year 3 durability figures do not replicate.
Regulatory and competitive standing
Bimekizumab, marketed as BIMZELX, already carries FDA approval for psoriatic arthritis dated September 2024, and UCB separately reported in May 2026 that bimekizumab beat risankizumab on ACR50 in the head-to-head BE BOLD trial (49.1% versus 38.4%, p=0.0078). Against that backdrop, the Year 3 abstract functions as a durability and payer-facing economic argument layered onto an already-validated and already-differentiated drug, rather than a new efficacy signal the market has been waiting on. The IL-17A inhibitor field in psoriatic arthritis includes 8 active trials and a 5% Phase 3 failure rate, with direct comparators ixekizumab, sonelokimab, and vunakizumab all in active Phase 3 development.
Caveats on the record
The BE COMPLETE registry record itself shows operational volatility during conduct: the primary completion date changed four times for a cumulative 341-day delay, and enrollment was revised twice before locking at 400 patients. That volatility predates database lock and completion in 2022 and has no bearing on the validity of the Year 3 follow-up data reported now, but it is part of the trial's documented history. The bigger open item is statistical: the abstract discloses no confidence intervals, p-values, or a concurrent control arm for its Year 3 figures, so the reported improvements cannot be isolated from time, standard-of-care background therapy, or selection effects among patients who remained in the open-label extension Press ReleasePress ReleaseJul 1, 2026.
This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.